PT - JOURNAL ARTICLE AU - Simona Stefania Bucsa AU - Petre Iacob Calistru TI - BNP level in patients with COPD exacerbations DP - 2013 Sep 01 TA - European Respiratory Journal PG - P782 VI - 42 IP - Suppl 57 4099 - http://erj.ersjournals.com/content/42/Suppl_57/P782.short 4100 - http://erj.ersjournals.com/content/42/Suppl_57/P782.full SO - Eur Respir J2013 Sep 01; 42 AB - Introduction:Exacerbations of COPD influence, by frequency and severity, the life prognosis of patients. Establishment of biomarkers useful as a predictor parameters of the COPD exacerbations is important given that these associated with the decline of lung function, with an increased risk of hospitalization, with high costs.Purpose:The utility of BNP in the prognosis of patients with COPD exacerbations; the BNP has been measured in patients with COPD exacerbations without symptoms or signs of pulmonary hypertension.Material and methods:The prospective study was carried out from 2010-2012.BNP was measured in 130 patients with stable COPD and exacerbations were monitored and relationship with serum BNPStudy visits have included: anamnesis,clinical examination,spirometry,BNPlevel, echocardiography, oxygen saturation during exacerbations.Results:During COPD exacerbations, the BNP was significantly higher than in the stable stage of the disease.BNP level was significantly higher in severe exacerbations compared with moderate and mild forms.No significant correlations between the BNP and the pulmonary function were detected.In exacerbation, the BNP in patients hospitalized was greater compared to those who are not hospitalized.The time period up to the initial exacerbation in subjects with high COPD level was significantly shorter.Conclusion: is considered that plasmatic level of BNP may be considered a useful non-invasive marker as a parameter predictor of the prognosis of COPD exacerbations."Acknowledgement: This paper is supported by the Sectoral Operational Programme Human Resources Development (SOPHRD) 2007-2013 financed from the European Social Fund and by the Romanian Government under the contract number POSDRU/107/1.5/S/82839".